Nowadays, IL-2 monotherapy is not the optimal and standard treatment for both metastatic renal cell carcinoma and MM but efforts to further improve the efficacy of IL-2 therapy are focused on combined therapies. The gene discussed is IL2; the disease is Miyoshi myopathy.